Skip to main content
Terug
Watch Compare

Perspective Therapeutics, Inc.

Datakwaliteit: 83%
CATX
NYSE Manufacturing Chemicals
€ 4,47
▲ € 0,10 (2,29%)
Marktkapitalisatie: 509,28 M
Prijs
€ 4,47
Marktkapitalisatie
509,28 M
Dagbereik
€ 4,33 — € 4,50
52-Weeksbereik
€ 1,74 — € 6,16
Volume
296.297
Openen € 4,36
50D / 200D Gem.
€ 4,68
4,52% below
50D / 200D Gem.
€ 3,58
24,80% above

Quick Summary

Belangrijkste Punten

Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -95,23 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-40,61%
Boven sectorgemiddelde (-53,47%)
ROIC-31,37%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,01
Onder sectorgemiddelde (0,31)
Current Ratio8,66
Interest CoverageN/A

Waardering

PE (TTM)
-4,94
Onder sectorgemiddelde (-1,47)
P/B Ratio2,10
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -4,9 -1,5
P/B 2,1 1,6
ROE % -40,6 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 0,0 0,3

ETFs Holding This Stock

BRSIX BRSIX
0,27% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0,01% weight
IRSSX IRSSX
0,01% weight
VVICX VVICX
0,01% weight
IRSIX IRSIX
0,01% weight
IIRSX IIRSX
0,01% weight
IRCIX IRCIX
0,01% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight
IWV logo IWV iShares Russell 3000 ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -103,12 M
ROE -40,61% ROA -34,06%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -95,23 M
ROIC -31,37% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 8,66
Interest Coverage N/A Asset Turnover N/A
Working Capital 157,88 M Tangible Book Value 242,22 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,94 Forward P/E N/A
P/B Ratio 2,10 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -18,70%
Market Cap 509,28 M Enterprise Value 484,16 M
Per Share
EPS (Diluted TTM) -1,40 Revenue / Share N/A
FCF / Share -0,84 OCF / Share -0,72
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 92,35%
SBC-Adj. FCF -102,55 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — 2,51 M 2,71 M
Net Income -103,12 M -79,28 M -46,51 M -7,27 M -3,39 M
EPS (Diluted) -1,40 -1,23 — — —
Gross Profit — — 1,43 M 4,62 M 5,12 M
Operating Income -113,56 M -90,89 M -40,94 M -7,39 M -3,45 M
EBITDA — — — — —
R&D Expenses 84,22 M 41,64 M 21,31 M 2,58 M 1,43 M
SG&A Expenses — — — — —
D&A 3,25 M 2,31 M — — —
Interest Expense — — 84.000,0 — —
Income Tax -793.000,0 -2,10 M -2,65 M 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 266,97 M 341,10 M 97,89 M 64,44 M 70,42 M
Total Liabilities 59,94 M 50,43 M 22,71 M 3,16 M 3,01 M
Shareholders' Equity 207,03 M 290,67 M 75,18 M 61,28 M 67,41 M
Total Debt 1,63 M 1,68 M 1,73 M — —
Cash & Equivalents 30,63 M 61,58 M 9,24 M 55,89 M 63,83 M
Current Assets 148,39 M 231,16 M 16,84 M 59,33 M 67,30 M
Current Liabilities 28,68 M 18,23 M 15,66 M 2,27 M 1,80 M